Deciphera Pharmaceuticals (NASDAQ:DCPH) Reaches New 52-Week High at $25.03

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $25.03 and last traded at $25.03, with a volume of 13028371 shares traded. The stock had previously closed at $14.65.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. raised their price objective on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Wednesday, March 20th. Stifel Nicolaus raised their target price on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, February 7th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $23.00.

Deciphera Pharmaceuticals Price Performance

The stock has a 50 day moving average of $15.59 and a two-hundred day moving average of $14.35.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings data on Tuesday, February 6th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The firm had revenue of $48.30 million during the quarter, compared to analyst estimates of $45.93 million. During the same period last year, the company posted ($0.60) EPS. The business’s quarterly revenue was up 32.9% compared to the same quarter last year. As a group, analysts expect that Deciphera Pharmaceuticals, Inc. will post -2.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Deciphera Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Diversified Trust Co lifted its holdings in Deciphera Pharmaceuticals by 6.5% in the 1st quarter. Diversified Trust Co now owns 12,747 shares of the company’s stock worth $201,000 after purchasing an additional 778 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Deciphera Pharmaceuticals by 96.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock worth $26,000 after buying an additional 997 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Deciphera Pharmaceuticals by 2.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 41,527 shares of the company’s stock worth $670,000 after buying an additional 1,117 shares during the period. Principal Financial Group Inc. increased its position in Deciphera Pharmaceuticals by 10.3% in the 3rd quarter. Principal Financial Group Inc. now owns 18,266 shares of the company’s stock worth $232,000 after buying an additional 1,699 shares during the period. Finally, Quest Partners LLC bought a new position in Deciphera Pharmaceuticals in the 4th quarter worth approximately $30,000. 70.96% of the stock is currently owned by institutional investors and hedge funds.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.